Original language | English |
---|---|
Pages (from-to) | 1035-1039 |
Number of pages | 5 |
Journal | Thorax |
Volume | 75 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 2020 |
Keywords
- COPD exacerbations
- respiratory infection
- NONINVASIVE VENTILATION
- PHYSIOTHERAPY
- MANAGEMENT
- CARE
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Thorax, Vol. 75, No. 12, 12.2020, p. 1035-1039.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Caring for patients with COPD and COVID-19
T2 - a viewpoint to spark discussion
AU - Simons, Sami O.
AU - Hurst, John R.
AU - Miravitlles, Marc
AU - Franssen, Frits M. E.
AU - Janssen, Daisy J. A.
AU - Papi, Alberto
AU - Duiverman, Marieke L.
AU - Kerstjens, Huib A. M.
N1 - Funding Information: Competing interests SOS has received speaker fees from AstraZeneca and research grants from GlaxoSmithKline, all outside the submitted work. JRH has received support to attend meetings, and payment for advisory work and educational activity, personally or to his employer (UCL), from pharmaceutical companies that make medicines to treat COPD. These include AstraZeneca, Boehringer Ingelheim, Chiesi and GlaxoSmithKline, all outside the submitted work. MM has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, Kamada, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, Spin Therapeutics, pH Pharma, Novartis, Sanofi and Grifols, and research grants from GlaxoSmithKline and Grifols, outside the submitted work. FF has received support to attend meetings, speakers and consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and TEVA; also he obtained research grants from AstraZeneca and Novartis. DJAJ has received speaker fees from AstraZeneca, Boehringer Ingelheim and Novartis in the previous 3 years. AP reports grants, personal fees, non-financial support and other from GlaxoSmithKline; grants, personal fees and nonfinancial support from AstraZeneca; grants, personal fees, non-financial support and other from Boehringer Ingelheim; grants, personal fees, non-financial support and other from Chiesi Farmaceutici; grants, personal fees, non-financial support and other from TEVA; personal fees, non-financial support and other from Mundipharma; personal fees, non-financial support and other from Zambon; personal fees, non-financial support and other from Novartis; grants, personal fees and non-financial support from Menarini; personal fees, non-financial support and other from Sanofi/Regeneron; personal fees from Roche, grants from Fondazione Maugeri, grants from Fondazione Chiesi, personal fees from Edmond Pharma, outside the submitted work. MLD reports grants, speaking fees and consultancy/ advisory board participation from/for Philips, ResMed, Vivisol, Fisher and Paykel, and Novartis, and all outside the submitted work and paid to her institution. HAMK reports grants and consultancy/advisory board participation from/for Novartis, GlaxoSmithKline and Boehringer Ingelheim, and a grant from Chiesi, all outside the submitted work and paid to his institution.
PY - 2020/12
Y1 - 2020/12
KW - COPD exacerbations
KW - respiratory infection
KW - NONINVASIVE VENTILATION
KW - PHYSIOTHERAPY
KW - MANAGEMENT
KW - CARE
U2 - 10.1136/thoraxjnl-2020-215095
DO - 10.1136/thoraxjnl-2020-215095
M3 - Article
C2 - 32878969
SN - 0040-6376
VL - 75
SP - 1035
EP - 1039
JO - Thorax
JF - Thorax
IS - 12
ER -